18 May 2013
Keywords: lek, construct, 7m, euro, biopharma, site, slovenian
Article | 09 October 2006
Slovenian drugmaker Lek, part of Novartis' Sandoz generics division, says that it is to develop and construct a new biopharmaceuticals
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 October 2006
17 May 2013
© 2013 thepharmaletter.com